Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The rise of new targets in melanoma.

The British journal of dermatology - 18 Nov 2025

Bai Xue, Flaherty Keith T

Abstract excerpt

Despite advancements in cancer treatment, the clinical options remain limited and therapeutic resistance inevitably develops. In melanoma, the second most commonly mutated driver oncogene is NRAS, which remains undruggable by small molecular agents. For those treated with BRAF/MEK combination therapy, in the setting of BRAF V600 mutations, or immunotherapies regardless of somatic genetic makeup, resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GTP Phosphohydrolases
Share to Melanoma
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Skin Neoplasms

Share to SOXE Transcription Factors

Share to Tumor Suppressor Protein p53

Share to Antineoplastic Agents

Share to Drug Resistance, Neoplasm

Source

Identifiers

PMID: 40570019
DOI: 10.1093/bjd/ljaf251

Genes

NRAS
BRAF
SOX10
SRY

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The rise of new targets in melanoma.PMID 40570019Read ↗

Identifying Ferroptosis Inducers, HDAC, and RTK Inhibitor Sensitivity in Melanoma Subtypes through Unbiased Drug Target PredictionSemantic proximity Read ↗

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanomaSemantic proximity Read ↗

Active repurposing of drug candidates for melanoma based on GWAS, PheWAS and a wide range of omics dataSemantic proximity Read ↗

Molecular Genomic Insights into Melanoma Associated Proteins PRAME and BAP1Semantic proximity Read ↗

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.Semantic proximity Read ↗

A novel combination treatment against melanoma with NRAS mutation and therapy resistance.Semantic proximity Read ↗

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.Semantic proximity Read ↗

The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone.Semantic proximity Read ↗

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapySemantic proximity Read ↗

ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanomaSemantic proximity Read ↗

Drug discovery and repurposing at Memorial Sloan Kettering Cancer Center: chemical biology drives translational medicine.Semantic proximity Read ↗

A mutation-resolved therapeutic atlas of NRAS-mutant melanoma reveals genotype-selective response to RAS(ON) inhibition and adaptive STAT3 survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.